General Information of Drug (ID: DMNORK8)

Drug Name
Jakafi
Synonyms
Ruxolitinib phosphate; 1092939-17-7; Ruxolitinib (phosphate); Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; UNII-436LRU32H5; Ruxolitinib phosphate salt; Ruxolitinib phosphate(INCB018424); CHEBI:66917; 436LRU32H5; J-501793; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate; Ruxolitinib phosphate [USAN]; Jaka
Indication
Disease Entry ICD 11 Status REF
Essential thrombocythemia 3B63.1Z Phase 3 [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 404.4
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 4
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 8
Chemical Identifiers
Formula
C17H21N6O4P
IUPAC Name
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
Canonical SMILES
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
InChI
InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
InChIKey
JFMWPOCYMYGEDM-XFULWGLBSA-N
Cross-matching ID
PubChem CID
25127112
ChEBI ID
CHEBI:66917
CAS Number
1092939-17-7
TTD ID
D0D8KQ
INTEDE ID
DR1454

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME
DE4LYSA CP3A4_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
C-X-C motif chemokine 10 (CXCL10) OTTLQ6S0 CXL10_HUMAN Gene/Protein Processing [3]
C-X-C motif chemokine 11 (CXCL11) OT353XE3 CXL11_HUMAN Gene/Protein Processing [3]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Gene/Protein Processing [3]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Gene/Protein Processing [3]
Mitochondrial brown fat uncoupling protein 1 OT0XMVWH UCP1_HUMAN Gene/Protein Processing [4]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Gene/Protein Processing [3]
Signal transducer and activator of transcription 5B (STAT5B) OTZVPEBT STA5B_HUMAN Post-Translational Modifications [5]
Tyrosine-protein kinase JAK1 (JAK1) OT0X3D17 JAK1_HUMAN Gene/Protein Processing [6]
Tyrosine-protein kinase JAK2 (JAK2) OTBIDOOR JAK2_HUMAN Gene/Protein Processing [6]
Vascular endothelial growth factor A, long form OTIM9MZ3 VEGFA_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27.
3 Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012 Dec;64(12):3856-66. doi: 10.1002/art.37691.
4 White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2015 Jan;17(1):57-67. doi: 10.1038/ncb3075. Epub 2014 Dec 8.
5 STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.
6 JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res. 2014;2014:283617. doi: 10.1155/2014/283617. Epub 2014 May 5.
7 Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors. Eur J Pharmacol. 2015 Oct 15;765:188-97. doi: 10.1016/j.ejphar.2015.08.037. Epub 2015 Aug 20.